Get started
REGENERON PHARMACEUTICALSREGENERON PHARMACEUTICALSREGENERON PHARMACEUTICALS

REGENERON PHARMACEUTICALS

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

1REGN trade ideas

Going Long on Regeneron (REGN)Regeneron Pharmaceuticals (REGN) is a stock that has seen an appreciation in its stock price since the beginning of the year. This trading idea focuses on the company's financial performance and its potential for future growth. Key Metrics: Gross Profit Ratio: Regeneron's gross profit ratio currently stands at 87.18%. This metric measures the efficiency and effectiveness of the company by dividing its gross profit by its total net sales. Research and Development (R&D) Expenditures: Regeneron invests $1 billion annually in R&D. This indicates the company's commitment to innovation and the development of new products. EBITDA: The company's earnings before interest, taxes, depreciation, and amortization (EBITDA) is currently $1.20 billion. This metric provides insights into the company's operating performance. Debt Ratio: Regeneron's debt ratio, which is the ratio of total debts to total assets, stands at 8.81. This indicates a relatively low level of debt compared to its assets. Trading Strategy: This trading idea focuses on companies with a moderate investment horizon and a somewhat high risk tolerance. The strategy is to buy the asset, REGN. Idea Core Logic: This strategy looks for companies that have a high gross profit ratio, indicating efficient and effective performance. It also focuses on companies that invest significantly in R&D, as this suggests a commitment to innovation and future growth. Additionally, companies with a high EBITDA and a low debt ratio are preferred, as they indicate strong financial performance and a healthy balance sheet. In the case of Regeneron Pharmaceuticals, it meets all these criteria with a gross profit ratio of 87.18%, 1 billion annual R&D expenditures, 1.20 billion EBITDA, and a debt ratio of 8.81. These factors suggest that Regeneron has a strong financial position and potential for future growth, making it an attractive investment opportunity. Technical Outlook Regeneron (REGN) bulls are looking to push the stock past a key resistance level at $759.49 as the next upside milestone if bulls maintain their dominance. Technical analysis indicates that a strong downtrend may be forthcoming with short positions being favored when the Commodity Channel Index (CCI) falls below -100. In today's session, Regeneron continued its 12-day uptrend by gaining 0.29%. The stock climbed to $779.89, showing positive momentum. In terms of returns, Regeneron has outperformed the Nasdaq by 0.88% so far this year. It currently has a market cap of $83.25 billion. There were 382,219 shares traded on the day, slightly below the average daily volume of 392,139 shares. Regeneron recently released its earnings figures, reporting 3.16 billion in revenue and earnings per share of 10.24. Market analysts had forecasted revenues of 3 billion and an EPS of 9.92. For the next earnings report, Regeneron is expected to announce revenues of 3.22 billion and an EPS of 10.8. Technical analysis indicates a possible new, strong downtrend for Regeneron. The Commodity Channel Index (CCI) indicator is below -100, suggesting that the market price is unusually low and below its moving average. A bullish engulfing candlestick pattern has also appeared on Regeneron's price chart.
NASDAQ:REGNLong
by NomolosAI
V can C bullish flag pattern breakout very soon in this Pharma.About:- Regeneron Pharmaceuticals, Inc. is a biotechnology company that discover, invent, develops, manufactures and commercializes medicines for the treatment of serious diseases. The company commercializes medicines and product candidates for eye diseases, allergic and inflammatory diseases, pain, infectious diseases, and rare diseases. Now about technical,,,so Regeneron pharmaceuticals in trading in bullish flag pattern since many months and now time has come for breakout. chances are high for breakout as it has done proper consolidation inside the bullish flag pattern...so i am expecting a breakout very soon,,keep an eye on monthly chart once breakout done, could be proper buy for this pharma ticker, and we can expect a rally towards 900+ levels..stop loss could be best support zone for this stock around 739. Thankyou guy's please don't forget to like and follow me for future updates.
NASDAQ:REGNLong
by TraderRahulPal
RectanglePrice is above the .236 of the trend up. Bound in a horizontal trading channel for the time being. Neutral pattern. Some trade inside the rectangle but it will eventually break to one side or the other. No recommendation. EPS (FWD) 42.93 PE (FWD) 17.09 Div Rate (TTM) - Short Interest 1.52% Market Cap $78.35B Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
NASDAQ:REGN
by lauralea
REGN Q3 earnings 11/3 @ 6:30amREGN Q3 September 2022 earnings are on 11/3 at 6:30am. Regeneron Pharmaceuticals (REGN) reported Q2 June 2022 earnings of $9.77 per share on revenue of $2.9 billion. The consensus earnings estimate was $8.53 per share on revenue of $2.8 billion. Revenue fell 44.4% compared to the same quarter a year ago. REGN short entry based on its $754 all time high major resistance level which it didn't even break through during the global covid pandemic in 2020. Plus, the nearest support going into earnings on 11/3 is the SMA50 around $663. Any short term pop up is an opportunity to get a higher strike put with a further dated expiry imo. Q3 September 2022 Consensus: EPS = $8.77 Revenue = $2.82 B SMA50 = 663.67 SMA100 = 634.61 SMA150 = 649.19 SMA200 = 641.40 52week high = 754.67 52week low = 538.01 Do your own due diligence, your risk is 100% your responsibility. This is for educational and entertainment purposes only. You win some or you learn some. Consider being charitable with some of your profit to help humankind. Good luck and happy trading friends... *3x lucky 7s of trading* 7pt Trading compass: Price action, entry/exit Volume average/direction Trend, patterns, momentum Newsworthy current events Revenue Earnings Balance sheet 7 Common mistakes: +5% portfolio trades, capital risk management Beware of analyst's motives Emotions & Opinions FOMO : bad timing, the market is ruthless, be shrewd Lack of planning & discipline Forgetting restraint Obdurate repetitive errors, no adaptation 7 Important tools: Trading View app!, Brokerage UI Accurate indicators & settings Wide screen monitor/s Trading log (pencil & graph paper) Big, organized desk Reading books, playing chess Sorted watch-list Checkout my indicators: Fibonacci VIP - volume Fibonacci MA7 - price pi RSI - trend momentum TTC - trend channel AlertiT - notification tickerTracker - MFI Oscillator www.tradingview.com
NASDAQ:REGNShort
by Options360
REGN shortREGN short trade based only on technical top resistance levels near its all-time high of $754. The trade duration can take several weeks for a significant pullback. REGN earnings are 11/3 pre-market. A short strategy could be to take an otm put position and then roll the strike up or roll the expiry to further dated every few days until the price drop occurs. Do your own due diligence, your risk is 100% your responsibility. This is for educational and entertainment purposes only. You win some or you learn some. Consider being charitable with some of your profit to help humankind. Good luck and happy trading friends... *3x lucky 7s of trading* 7pt Trading compass: Price action, entry/exit Volume average/direction Trend, patterns, momentum Newsworthy current events Revenue Earnings Balance sheet 7 Common mistakes: +5% portfolio trades, capital risk management Beware of analyst's motives Emotions & Opinions FOMO : bad timing, the market is ruthless, be shrewd Lack of planning & discipline Forgetting restraint Obdurate repetitive errors, no adaptation 7 Important tools: Trading View app!, Brokerage UI Accurate indicators & settings Wide screen monitor/s Trading log (pencil & graph paper) Big, organized desk Reading books, playing chess Sorted watch-list Checkout my indicators: Fibonacci VIP - volume Fibonacci MA7 - price pi RSI - trend momentum TTC - trend channel AlertiT - notification tickerTracker - MFI Oscillator www.tradingview.com
NASDAQ:REGNShort
by Options360